Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | NPEPPS | P55786 | 8/20 | 0.36 |
| ▸ | ANPEP | P15144 | 8/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31406536 | 1.00 | ADORA2A (0.36) | ADORA2AADORA2BNPEPPSANPEPSMN1; SMN2 | |
| SCHEMBL26981136 | 0.87 | ADORA2A (0.38) | ADORA2AADORA2BNPEPPSANPEPSMN1; SMN2 | |
| SCHEMBL29835052 | 0.87 | ADORA2A (0.38) | ADORA2AADORA2BNPEPPSANPEPSMN1; SMN2 | |
| SCHEMBL28521252 | 0.86 | HTR2C (0.31) | — | |
| SCHEMBL31192291 | 0.86 | HTR2C (0.31) | — | |
| SCHEMBL31228871 | 0.84 | NPEPPS (0.35) | ADORA2AADORA2BNPEPPSANPEPSMN1; SMN2 | |
| SCHEMBL28758954 | 0.83 | SLC29A1 (0.37) | ADORA2AADORA2BNPEPPSANPEP | |
| SCHEMBL30042226 | 0.78 | PI4KA (0.39) | ADORA2AADORA2BSMN1; SMN2TP53LMNA | |
| SCHEMBL2463541 | 0.78 | ADORA3 (0.50) | ADORA2AADORA2BSMN1; SMN2 | |
| SCHEMBL16987222 | 0.78 | TARS1 (0.38) | TP53LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120153078-A | RNA molecules encoding RSV-F and vaccines containing the same | 辉瑞大药厂 | 2025-06-13 | — | — | CN | disclosed |
| CN-120129688-A | Efficient method for preparing highly purified 5' -capped oligonucleotides | 垂林克生物技术有限公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-119563026-A | MRNA of novel coronavirus S protein and application thereof | 深圳深信生物科技有限公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-119562826-A | Stable pre-fusion HMPV fusion proteins | MSD国际商务股份有限公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-119522284-A | Lipid Nanoparticle (LNP) based ocular delivery | 克里斯珀医疗股份公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-113423418-B | Treatment of cilia disease | 埃泽瑞斯公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-119095964-A | Multi-tail and multi-cap mRNA and uses thereof | 博德研究所 | 2024-12-06 | — | — | CN | disclosed |
| CN-119053705-A | Methods and compositions for treating lipoprotein-related diseases | 克里斯珀医疗股份公司 | 2024-11-29 | — | — | CN | disclosed |
| CN-119032176-A | Methods and compositions for treating angiopoietin-like 3 (ANGPTL 3) related conditions | 克里斯珀医疗股份公司 | 2024-11-26 | — | — | CN | disclosed |
| CN-118949075-A | Treatment of cilia disease | 埃泽瑞斯公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-116133652-A | Method for preparing lipid nanoparticles | 摩登纳特斯有限公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-109312338-B | CRISPR/CAS related methods and compositions for treating herpes simplex virus | 爱迪塔斯医药公司 | 2022-09-27 | — | — | CN | disclosed |
| CN-114746398-A | Headgroup lipid compounds and compositions for intracellular delivery of therapeutic agents | 摩登纳特斯有限公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-114728887-A | Branched tail end lipid compounds and compositions for intracellular delivery of therapeutic agents | 摩登纳特斯有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114729392-A | Systems and methods for barcoding cells and cell beads | 10X基因组学有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114728886-A | Carbonate-containing lipid compounds and compositions for intracellular delivery of therapeutic agents | 摩登纳特斯有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-113874503-A | Systems and methods for modulating CRISPR activity | 辛瑟高公司 | 2021-12-31 | — | — | CN | disclosed |
| CN-113677793-A | Stable CRISPR complexes | 辛瑟高公司 | 2021-11-19 | — | — | CN | disclosed |
| CN-113423418-A | Treatment of cilia disease | 埃泽瑞斯公司 | 2021-09-21 | — | — | CN | disclosed |
| CN-110546262-A | compositions and methods for treating hemoglobinopathies | NOVARTIS AG | 2019-12-06 | — | — | CN | disclosed |